MDGL Insider Transactions — Page 7
1,874 retained open-market purchase and sale rows from SEC Forms 3, 4 and 5, newest first. This page shows rows 601–700; provenance stays internal.
| Insider profile | Role | Date | Transaction | Shares | Price |
|---|---|---|---|---|---|
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2025-03-05 | Sale | 1,146.0 | $338.09 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2025-03-05 | Sale | 1,777.0 | $336.78 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2025-03-05 | Sale | 900.0 | $335.15 |
| Kelley Shannon T | General Counsel | 2025-03-03 | Sale | 415.0 | $335.0 |
| Dier Mardi | SVP and CFO | 2025-03-03 | Sale | 774.0 | $323.54 |
| Dier Mardi | SVP and CFO | 2025-03-03 | Sale | 1,187.0 | $325.89 |
| Huntsman Carole | Chief Commercial Officer | 2025-03-03 | Sale | 563.0 | $335.0 |
| Huntsman Carole | Chief Commercial Officer | 2025-03-03 | Sale | 100.0 | $329.64 |
| Huntsman Carole | Chief Commercial Officer | 2025-03-03 | Sale | 100.0 | $327.49 |
| Huntsman Carole | Chief Commercial Officer | 2025-03-03 | Sale | 100.0 | $326.34 |
| Huntsman Carole | Chief Commercial Officer | 2025-03-03 | Sale | 200.0 | $324.59 |
| Huntsman Carole | Chief Commercial Officer | 2025-03-03 | Sale | 200.0 | $323.65 |
| Huntsman Carole | Chief Commercial Officer | 2025-03-03 | Sale | 300.0 | $320.21 |
| Huntsman Carole | Chief Commercial Officer | 2025-03-03 | Sale | 200.0 | $314.74 |
| Huntsman Carole | Chief Commercial Officer | 2025-03-03 | Sale | 71.0 | $313.08 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2025-02-28 | Sale | 175.0 | $341.55 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2025-02-28 | Sale | 1,052.0 | $340.99 |
| Daly James M | Director | 2025-02-27 | Sale | 770.0 | $348.94 |
| Daly James M | Director | 2025-02-27 | Sale | 14,302.0 | $347.39 |
| Daly James M | Director | 2025-02-27 | Sale | 398.0 | $346.9 |
| BATE KENNETH | Director | 2025-02-27 | Sale | 216.0 | $360.07 |
| BATE KENNETH | Director | 2025-02-27 | Sale | 2,024.0 | $359.21 |
| BATE KENNETH | Director | 2025-02-27 | Sale | 3,548.0 | $358.33 |
| BATE KENNETH | Director | 2025-02-27 | Sale | 2,038.0 | $357.27 |
| BATE KENNETH | Director | 2025-02-27 | Sale | 2,791.0 | $356.51 |
| BATE KENNETH | Director | 2025-02-27 | Sale | 8,545.0 | $355.08 |
| BATE KENNETH | Director | 2025-02-27 | Sale | 238.0 | $353.83 |
| BATE KENNETH | Director | 2025-02-27 | Sale | 500.0 | $351.99 |
| BATE KENNETH | Director | 2025-02-27 | Sale | 100.0 | $351.01 |
| Huntsman Carole | Chief Commercial Officer | 2025-01-24 | Sale | 347.0 | $335.24 |
| Sibold William John | President and CEO | 2025-01-24 | Sale | 1,584.0 | $335.24 |
| Taub Rebecca | Pres., R&D, and CMO | 2025-01-24 | Sale | 648.0 | $335.24 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2025-01-24 | Sale | 103.0 | $335.24 |
| Kelley Shannon T | General Counsel | 2025-01-17 | Sale | 277.0 | $273.41 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2025-01-17 | Sale | 442.0 | $273.41 |
| Taub Rebecca | Pres., R&D, and CMO | 2025-01-17 | Sale | 1,689.0 | $273.41 |
| CRAVES FRED B | Director | 2024-12-03 | Sale | 520.0 | $315.9 |
| CRAVES FRED B | Director | 2024-12-03 | Sale | 3,080.0 | $315.21 |
| CRAVES FRED B | Director | 2024-11-25 | Sale | 1,200.0 | $350.71 |
| CRAVES FRED B | Director | 2024-11-25 | Sale | 2,200.0 | $350.08 |
| Huntsman Carole | Chief Commercial Officer | 2024-11-21 | Sale | 688.0 | $316.92 |
| Levy Richard S | Director | 2024-11-07 | Sale | 5,000.0 | $350.0 |
| Levy Richard S | Director | 2024-11-01 | Sale | 300.0 | $304.29 |
| Levy Richard S | Director | 2024-11-01 | Sale | 800.0 | $302.25 |
| Levy Richard S | Director | 2024-11-01 | Sale | 1,100.0 | $301.22 |
| Levy Richard S | Director | 2024-11-01 | Sale | 2,800.0 | $300.1 |
| Sibold William John | President and CEO | 2024-09-09 | Sale | 6,363.0 | $243.83 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2024-06-14 | Sale | 1,900.0 | $280.0 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2024-06-12 | Sale | 2,000.0 | $285.0 |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2024-05-21 | Sale | 1,036.0 | $231.34 |
| CRAVES FRED B | Director | 2024-05-14 | Sale | 100.0 | $219.9 |
| CRAVES FRED B | Director | 2024-05-14 | Sale | 1,000.0 | $218.99 |
| CRAVES FRED B | Director | 2024-05-14 | Sale | 1,100.0 | $217.86 |
| CRAVES FRED B | Director | 2024-05-14 | Sale | 721.0 | $216.98 |
| CRAVES FRED B | Director | 2024-05-14 | Sale | 375.0 | $216.08 |
| CRAVES FRED B | Director | 2024-05-14 | Sale | 1,804.0 | $214.68 |
| CRAVES FRED B | Director | 2024-05-14 | Sale | 2,190.0 | $213.85 |
| CRAVES FRED B | Director | 2024-05-14 | Sale | 1,363.0 | $212.85 |
| CRAVES FRED B | Director | 2024-05-14 | Sale | 5,009.0 | $211.84 |
| CRAVES FRED B | Director | 2024-05-14 | Sale | 8,827.0 | $210.99 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-08 | Sale | 200.0 | $248.58 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-08 | Sale | 407.0 | $247.76 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-08 | Sale | 600.0 | $246.98 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-08 | Sale | 300.0 | $245.69 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-08 | Sale | 945.0 | $244.79 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-08 | Sale | 224.0 | $243.25 |
| FRIEDMAN PAUL A | Director | 2024-04-08 | Sale | 4,866.0 | $248.59 |
| FRIEDMAN PAUL A | Director | 2024-04-08 | Sale | 3,464.0 | $247.76 |
| FRIEDMAN PAUL A | Director | 2024-04-08 | Sale | 5,028.0 | $246.96 |
| FRIEDMAN PAUL A | Director | 2024-04-08 | Sale | 2,078.0 | $245.71 |
| FRIEDMAN PAUL A | Director | 2024-04-08 | Sale | 5,663.0 | $244.86 |
| FRIEDMAN PAUL A | Director | 2024-04-08 | Sale | 3,730.0 | $244.12 |
| FRIEDMAN PAUL A | Director | 2024-04-08 | Sale | 1,441.0 | $242.95 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-05 | Sale | 5,278.0 | $245.53 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-05 | Sale | 2,079.0 | $244.45 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-05 | Sale | 8,989.0 | $243.33 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-05 | Sale | 8,817.0 | $242.61 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-05 | Sale | 700.0 | $241.14 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-05 | Sale | 1,643.0 | $240.11 |
| FRIEDMAN PAUL A | Director | 2024-04-05 | Sale | 444.0 | $245.92 |
| FRIEDMAN PAUL A | Director | 2024-04-05 | Sale | 5,228.0 | $245.35 |
| FRIEDMAN PAUL A | Director | 2024-04-05 | Sale | 3,966.0 | $244.22 |
| FRIEDMAN PAUL A | Director | 2024-04-05 | Sale | 9,264.0 | $243.2 |
| FRIEDMAN PAUL A | Director | 2024-04-05 | Sale | 6,679.0 | $242.42 |
| FRIEDMAN PAUL A | Director | 2024-04-05 | Sale | 612.0 | $241.15 |
| FRIEDMAN PAUL A | Director | 2024-04-05 | Sale | 1,420.0 | $240.1 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-04 | Sale | 100.0 | $248.23 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-04 | Sale | 711.0 | $247.23 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-04 | Sale | 1,653.0 | $246.01 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-04 | Sale | 2,734.0 | $245.06 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-04 | Sale | 435.0 | $244.01 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-04 | Sale | 3,085.0 | $242.71 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-04 | Sale | 5,619.0 | $241.85 |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-04 | Sale | 4,200.0 | $240.88 |
| FRIEDMAN PAUL A | Director | 2024-04-04 | Sale | 200.0 | $248.43 |
| FRIEDMAN PAUL A | Director | 2024-04-04 | Sale | 737.0 | $247.14 |
| FRIEDMAN PAUL A | Director | 2024-04-04 | Sale | 1,558.0 | $246.13 |
| FRIEDMAN PAUL A | Director | 2024-04-04 | Sale | 2,549.0 | $245.14 |
| FRIEDMAN PAUL A | Director | 2024-04-04 | Sale | 627.0 | $244.31 |
| FRIEDMAN PAUL A | Director | 2024-04-04 | Sale | 1,467.0 | $243.0 |